Tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-6 levels are elevated in the tumor tissues and sera and associated with poor survival, increased tumor burden, and disease progression in patients with CRC [12,13]. This evidence concerns the gene IL6 and neoplasm.